Drug Discovery

Aerie Pharmaceuticals agrees to acquire Avizorex Pharma

Aerie Pharmaceuticals, an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, announced the signing of an agreement (the “Agreement”) for the acquisition of Avizorex Pharma, S.L. (“AVX Pharma” or “AVX”), a Spanish ophthalmic pharmaceutical company developing therapeutics for the treatment of dry eye disease.

Alkermes to buy Rodin Therapeutics for up to $950m

Alkermes has signed an agreement to acquire biopharmaceutical company Rodin Therapeutics in a deal valued at around $950m.

Roche to buy clinical-stage biotechnology firm Promedior in $1.39bn deal

Roche has agreed to acquire US-based clinical-stage biotechnology company Promedior in a deal valued at around $1.39bn.

EpicentRx closes $35m series D financing to support development of small molecule immunotherapy and oncolytic viral platform

EpicentRx, a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with minimal toxicity, announced today that it has raised a $35 million Series D financing using the Silicon Valley based life-science focused investment bank, Biotech Alliances International.

Finch Therapeutics, Takeda expand collaboration to develop microbiome therapeutics

Finch Therapeutics Group, Inc. (“Finch”) and Takeda Pharmaceutical Company Limited (“Takeda”; TSE:4502/NYSE:TAK) announced today the expansion of their collaboration to develop microbiome-based therapeutics using Finch’s Human-First Discovery platform.

RDD Pharma signs LOI to acquire Naia Rare Diseases

RDD Pharma, a company focused on orphan and innovative therapies for gastrointestinal disorders entered into a non-binding letter of intent (LOI) to acquire Naia Rare Diseases ("Naia"), a biopharmaceutical company developing drugs for Short Bowel Syndrome ("SBS") and other rare gastrointestinal diseases.

Merck to acquire Calporta Therapeutics for $576m

COI Pharmaceuticals announced that Merck has agreed to acquire Calporta Therapeutics in a deal valued at around $576m.

NEC and VAXIMM announce collaboration to advance personalized neoantigen cancer vaccines

NEC has the option for development and commercialization rights to the program worldwide, except for China and other Asian territories outside of Japan

ATAI Life Sciences and Cyclica launch joint venture to revolutionise drug development for mental health disorders

ATAI Life Sciences AG, a global biotech platform that envisions an end to mental illnesses, and Cyclica Inc., a leading biotechnology company that leverages artificial intelligence and computational biophysics to streamline the drug discovery process, have launched a joint venture aimed at changing the paradigm in which mental health disorders are treated.